^
    CANCER:

    Endometrial Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    nivolumab
    PD1 inhibitor
    dostarlimab-gxly
    		0
    PD1 inhibitor
    pembrolizumab
    tislelizumab
    zimberelimab
    retifanlimab-dlwr
    1
    DNA synthesis inhibitor
    cisplatin
    gemcitabine
    2
    Topoisomerase II inhibitor
    pegylated liposomal doxorubicin
    doxorubicin hydrochloride
    3
    mTOR inhibitor
    temsirolimus
    4
    VEGF-A inhibitor
    bevacizumab
    5
    HER2 inhibitor
    trastuzumab
    6
    Aromatase inhibitor, mTOR inhibitor
    everolimus + letrozole
    CDK4 inhibitor + CDK6 inhibitor
    		7
    CDK4 inhibitor, CDK6 inhibitor
    ribociclib
    abemaciclib
    8
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    capecitabine + mitomycin
    9
    Bifunctional alkylating agent, DNA synthesis inhibitor
    cisplatin + ifosfamide
    10
    Estrogen receptor antagonist
    tamoxifen
    tamoxifen
    11
    Tubulin polymerization promoter, Bcl2 inhibitor
    carboplatin + paclitaxel
    paclitaxel
    12
    Tubulin polymerization promoter
    carboplatin
    13
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    14
    Topoisomerase I inhibitor
    topotecan
    15
    Bifunctional alkylating agent
    ifosfamide
    16
    Estrogen receptor antagonist, Progesterone receptor agonist
    tamoxifen + megestrol
    17
    Progesterone receptor agonist
    megestrol
    18
    Selective estrogen receptor degrader
    fulvestrant
    19
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    BNT323
    fam-trastuzumab deruxtecan-nxki
    olaparib
    		20
    PARP inhibitor
    niraparib
    talazoparib
    21
    WEE1 inhibitor
    ZN-c3
    AZD1775
    22
    PD-L1 inhibitor
    durvalumab
    avelumab
    23
    PD1 inhibitor, PARP inhibitor
    niraparib + dostarlimab-gxly
    24
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    25
    Multi-tyrosine kinase inhibitor
    pazopanib
    ponatinib
    26
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    27
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + sintilimab
    nivolumab + cabozantinib tablet
    28
    KRAS G12C inhibitor
    adagrasib
    sotorasib
    29
    Aromatase inhibitor
    Aromatase inhibitor
    letrozole
    30
    ATR inhibitor
    BAY 1895344
    31
    XPO1 inhibitor
    selinexor
    32
    VEGF-A inhibitor, PARP inhibitor
    bevacizumab + rucaparib
    33
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    34
    DKK1 protein inhibitor
    DKN-01
    35
    CAR-T immunotherapy
    TC-A101
    36
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    37
    Chemotherapy
    AIM
    38
    Immunotherapy
    Immunotherapy
    39
    Immunotherapy, Tyrosine kinase inhibitor
    Immunotherapy + Tyrosine kinase inhibitor
    40
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + doxorubicin hydrochloride
    41
    Bifunctional alkylating agent, Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel + ifosfamide
    42
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    carboplatin + docetaxel
    43
    Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    cisplatin + paclitaxel + doxorubicin hydrochloride
    44
    CLDN18.2-targeted antibody-drug conjugate
    CLDN18.2-targeted antibody-drug conjugate
    45
    Chk1 inhibitor, Chk2 inhibitor
    ACR-368
    46
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    47
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    48
    EZH1 inhibitor, EZH2 inhibitor
    CPI-0209
    49
    β-catenin inhibitor, CBP inhibitor, Wnt signalling pathway inhibitor
    PRI724
    50
    VEGFR inhibitor, PD1 inhibitor
    sintilimab + fruquintinib
    51
    Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
    gemcitabine + docetaxel
    52
    PI3K inhibitor, mTOR inhibitor
    LY3023414
    RTB101
    53
    PI3K inhibitor, MEK1 inhibitor, AKT inhibitor
    cobimetinib + RG7440
    54
    Aromatase inhibitor, CDK4 inhibitor, CDK6 inhibitor
    palbociclib + letrozole
    mirvetuximab soravtansine-gynx
    		55
    Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor
    STRO-002
    MORAb-202
    56
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    trastuzumab + lapatinib
    57
    CDK2 inhibitor, CDK9 inhibitor
    CYC065
    58
    pan-RAF inhibitor, EGFR inhibitor
    BGB-283
    59
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor
    VS-6766
    60
    PARP inhibitor, TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    rucaparib + sacituzumab govitecan-hziy
    61
    FGFR inhibitor, VEGFR inhibitor, PDGFR α-β inhibitor, Tyrosine kinase inhibitor, PARP inhibitor
    rucaparib + E 3810
    62
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ado-trastuzumab emtansine
    63
    Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor, PARP inhibitor
    rucaparib + mirvetuximab soravtansine-gynx
    64
    Folate receptor 1-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    PRO1184
    65
    PD-L1 inhibitor, VEGF-A inhibitor, PARP inhibitor
    bevacizumab + atezolizumab + rucaparib
    66
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    67
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    pyrotinib
    afatinib
    A66
    		68
    PI3K inhibitor
    GDC-0941
    MEN1611
    69
    PI3Kβ inhibitor, PI3K inhibitor
    A66 + AZD6482
    GSK2636771 + A66
    70
    PI3Kβ inhibitor, Apoptosis inducer
    TGX-221
    71
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    72
    HER2-targeted antibody-drug conjugate, DNA replication inhibitor
    DHES0815A
    73
    FGFR2 inhibitor
    RLY-4008
    74
    PI3K inhibitor, AKT inhibitor
    RG7440
    75
    SOS1 inhibitor, MEK inhibitor
    trametinib + BI-3406
    76
    CD3 agonist, CLDN6 inhibitor
    CTIM-76
    77
    VEGF-A inhibitor, Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor
    bevacizumab + STRO-002
    78
    BET inhibitor
    JQ-1
    79
    PARP inhibitor, ATM kinase inhibitor
    olaparib + KU-55933
    80
    EZH2 inhibitor, HOTAIR inhibitor
    tazemetostat + AC1Q3QWB
    pemigatinib
    		81
    FGFR inhibitor
    infigratinib
    futibatinib
    82
    FGFR inhibitor, AKT inhibitor
    futibatinib + TAS-117
    futibatinib + MK-2206
    83
    Tyrosine kinase inhibitor
    PD173074
    84
    PI3Kβ inhibitor
    AZD6482
    GSK2636771
    85
    pan-RAF inhibitor
    AZ 628
    86
    SF3B1 inhibitor, RNA splicing modulator
    SSA
    87
    MEK inhibitor
    PD-0325901
    88
    FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
    TKI258
    No biomarker
    HER-2 expression
    HER-2 amplification
    HER-2 overexpression
    HER-2 positive
    ER positive
    ER expression
    MSI-H/dMMR
    ARID1A mutation
    FOLR1 expression
    KRAS mutation
    KRAS G12C
    KRAS G12D
    BRCA1 mutation
    CTNNB1 mutation
    YWHAE-NUTM2B translocation
    PTEN deletion
    PTEN mutation
    TP53 mutation
    TP53 wild-type
    POLE mutation
    POLE V411L
    POLE P286R
    PTEN-L
    TP53 overexpression
    TP53 amplification
    TMB-H
    PALB2 deletion
    MSH6 F1088fs
    MSI-H/dMMR + MLH1 deletion
    PALB2 mutation
    MLH1 deletion
    MSH6 mutation
    HRD + BRCA1 mutation
    NTRK1 fusion
    NTRK2 fusion
    NTRK3 fusion
    BRCA2 mutation
    PD-L1 expression
    KIT expression
    FGFR2 S252W
    DKK1 overexpression
    MCL1 amplification
    ATM PI2629fs*
    PIK3R1 mutation
    AKT1 mutation
    EGFR E690K
    TSC1 mutation
    TSC2 mutation
    FGFR2-BICC1 fusion
    FGFR2-OFD1 fusion
    LRP1B mutation
    MSH2 deletion
    CXCL10 elevation
    CXCL9 elevation
    CCNE1 overexpression
    ALPP expression
    MSH2 deletion + MSH6 deletion
    MLH1 deletion+ PMS2 deletion
    FAT2 mutation
    MLH1 methylation + MSI-H/dMMR + TMB-H
    MLH1 methylation + MSI-H/dMMR
    HRD + BRCA2 mutation
    FGFR3-TACC3 fusion
    YWHAE-NUTM2A translocation
    AKT1 mutation + mTOR mutation
    ATM overexpression
    FGFR2 N550K
    FGFR2 mutation
    FGFR2 N549K
    FGFR2 K310R
    FGFR2 B252W
    FGFR2 expression
    CLDN18.2 expression
    SOX17 overexpression
    TROP2 overexpression
    FGFR3 mutation
    CLDN6 expression
    PIK3CA mutation + KRAS mutation
    PIK3CA mutation
    CDKN1A overexpression
    PD-L2 overexpression
    NRAS mutation
    HRAS mutation
    SF3B1 K666N
    MRE11A mutation
    ERBB3 expression
    BRD4 overexpression
    PIK3CA H1047R
    PIK3CA mutation + PTEN mutation + KRAS mutation